Quest for the right Drug

|
עמוד הבית / דסקובי 10 מ"ג/מ"ג 200 / מידע מעלון לרופא

דסקובי 10 מ"ג/מ"ג 200 DESCOVY 200 MG/10 MG (EMTRICITABINE, TENOFOVIR ALAFENAMIDE FUMARATE)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

פומי : PER OS

צורת מינון:

טבליות מצופות פילם : FILM COATED TABLETS

Posology : מינונים

4.2     Posology and method of administration

Therapy should be initiated by a physician experienced in the management of HIV infection.
Posology

Descovy should be administered as shown in Table 1.



Table 1: Dose of Descovy according to third agent in the HIV treatment regimen 
Dose of Descovy                  Third agent in HIV treatment regimen (see section 4.5)
Descovy 200/10 mg once           Atazanavir with ritonavir or cobicistat daily                            Darunavir with ritonavir or cobicistat1 Lopinavir with ritonavir
Descovy 200/25 mg once           Dolutegravir, efavirenz, maraviroc,
daily                            nevirapine, rilpivirine, raltegravir 1   Descovy 200/10 mg in combination with darunavir 800 mg and cobicistat 150 mg, administered as a fixed-dose combination tablet, was studied in treatment-naive subjects, see section 5.1.

Missed doses
If the patient misses a dose of Descovy within 18 hours of the time it is usually taken, the patient should take Descovy as soon as possible and resume the normal dosing schedule. If a patient misses a dose of Descovy by more than 18 hours, the patient should not take the missed dose and simply resume the usual dosing schedule.

If the patient vomits within 1 hour of taking Descovy another tablet should be taken.

Elderly
No dose adjustment of Descovy is required in elderly patients (see sections 5.1 and 5.2).
Renal impairment
No dose adjustment of Descovy is required in adults or adolescents (aged at least 12 years and of at least 35 kg body weight) with estimated creatinine clearance (CrCl) ≥ 30 mL/min.

Descovy should be discontinued in patients with estimated CrCl that declines below 30 mL/min during treatment (see section 5.2).

No dose adjustment of Descovy is required in adults with end stage renal disease (estimated CrCl < 15 mL/min) on chronic haemodialysis; however, Descovy should generally be avoided but may be used in these patients if the potential benefits are considered to outweigh the potential risks (see sections 4.4 and 5.2). On days of haemodialysis, Descovy should be administered after completion of haemodialysis treatment.

Descovy should be avoided in patients with estimated CrCl ≥ 15 mL/min and < 30 mL/min, or < 15 mL/min who are not on chronic haemodialysis, as the safety of Descovy has not been established in these populations.

No data are available to make dose recommendations in children less than 18 years with end stage renal disease.

Hepatic impairment
No dose adjustment of Descovy is required in patients with hepatic impairment.

Paediatric population
The safety and efficacy of Descovy in children younger than 12 years of age, or weighing < 35 kg, have not yet been established. No data are available.

Method of administration

Oral use.
Descovy should be taken once daily with or without food (see section 5.2). It is recommended that the film-coated tablet is not be chewed or crushed due to the bitter taste and it may impact the absorption of Descovy.


For patients who are unable to swallow the tablet whole, the tablet may be split in half and both halves taken one after the other, ensuring that the full dose is taken immediately.

שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל לא צוין
הגבלות לא צוין

בעל רישום

GILEAD SCIENCES ISRAEL LTD

רישום

158 05 34949 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

07.08.22 - עלון לרופא 04.01.23 - עלון לרופא 08.05.23 - עלון לרופא 16.05.23 - עלון לרופא 16.05.24 - עלון לרופא

עלון מידע לצרכן

25.11.18 - עלון לצרכן 07.08.22 - עלון לצרכן אנגלית 07.08.22 - עלון לצרכן עברית 07.08.22 - עלון לצרכן ערבית 04.01.23 - עלון לצרכן אנגלית 04.01.23 - עלון לצרכן עברית 08.05.23 - עלון לצרכן אנגלית 16.05.23 - עלון לצרכן אנגלית 08.05.23 - עלון לצרכן עברית 16.05.23 - עלון לצרכן עברית 16.05.23 - עלון לצרכן ערבית 16.05.24 - עלון לצרכן אנגלית 16.05.24 - עלון לצרכן עברית 16.05.24 - עלון לצרכן ערבית 20.11.18 - החמרה לעלון 19.03.19 - החמרה לעלון 07.10.20 - החמרה לעלון 08.03.22 - החמרה לעלון 13.04.22 - החמרה לעלון 04.01.23 - החמרה לעלון 16.05.24 - החמרה לעלון

לתרופה במאגר משרד הבריאות

דסקובי 10 מ"ג/מ"ג 200

קישורים נוספים

RxList WebMD Drugs.com